Source comparison
BPC-157 for Stomach Ulcers: Clinical Evidence Comparison
University of Zagreb (ethanol model) Controlled rat trial, n=60 88% at 24h vs 12% saline Angiogenesis, collagen synthesis No Indomethacin NSAID model Comparative rat study 76% vs 41% ranitidine VEGF upregulation, eNOS activation Cysteamine duodenal ulcer 7-day
This comparison does not assign a generated winner or score.
- University of Zagreb (ethanol model)
- Controlled rat trial, n=60
- 88% at 24h vs 12% saline
- Angiogenesis, collagen synthesis
- No
- Indomethacin NSAID model
- Comparative rat study
- 76% vs 41% ranitidine
- VEGF upregulation, eNOS activation
- Cysteamine duodenal ulcer
- 7-day treatment, recurrence tracked
- 92% recurrence prevention vs 33% control
- Collagen deposition, tissue tensile strength
- Human case reports (internet forums)
- Anecdotal self-administration
- Symptom resolution reported in 48–96h
- Unknown. No biopsy or endoscopy confirmation
- Self-reported only
- FDA-approved ulcer drugs (omeprazole)
- Phase III human trials
- 60–80% healing at 4–8 weeks
- Acid suppression (no tissue repair)
- Yes. Extensive
- Clinical Reality Assessment
- No controlled human trials exist for BPC-157 in ulcer treatment
- Animal efficacy does not guarantee human safety or effectiveness
- Regulatory approval requires Phase I, II, III trials. None completed
- BPC-157 remains unapproved for human medical use